This document outlines coverage criteria for the medication Truvada (emtricitabine/tenofovir disoproxil fumarate) for the treatment of HIV infection, post-exposure prophylaxis to reduce the risk of HIV infection after occupational or non-occupational exposure, and pre-exposure prophylaxis to reduce the risk of sexually acquired HIV infection in high-risk adults. Initial authorization is approved for PrEP for 6 months if screening shows negative HIV status and counseling on safe sex practices has occurred. Reauthorization requires continued screening, counseling, and confirmation of high risk status. PEP is authorized for 1 month if initiated within 72 hours of exposure. Treatment of HIV infection is authorized for 60 months.

1. Confidential and Proprietary, © 2013 United HealthCare Services, Inc.
1
UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Notification - Standard
Medication Truvada®
(emtricitabine/tenofovir disoproxil fumarate)
Date Approved 11/2012
Date Revised 04/2013
1. Background:
Truvada®
(emtricitabine/tenofovir disoproxil fumarate) is a combination of Emtriva®
(emtricitabine) and Viread®
(tenofovir disoproxil fumarate), both nucleoside analog HIV-1
reverse transcriptase inhibitors. Truvada is indicated in combination with other antiretroviral
agents for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and
older. Truvada is indicated in combination with safer sex practices for pre-exposure prophylaxis
(PrEP) to reduce the risk of sexually acquired HIV-1 in adults at high risk.
Prior to initiating Truvada for PrEP: if clinical symptoms consistent with acute viral infection are
present and recent (<1 month) exposures are suspected, delay starting PrEP for at least one
month and reconfirm negative HIV-1 status or use a test approved by the FDA as an aid in the
diagnosis of HIV-1 infection, including acute or primary HIV-1 infection. While using Truvada
for PrEP -HIV-1 screening tests should be repeated at least every 3 months.
The use of Truvada as a 2-drug post exposure antiretroviral regimen for the prevention of HIV
infection after either an occupational or non-occupational exposure to the HIV virus is supported
by guidelines from both the Centers for Disease Control and the World Health Organization2,3
.
Members who are on combination therapy with another antiretroviral medication for the
treatment of HIV infection as documented in the claims history will be allowed to continue to
receive coverage for their current therapy. Members who are on Truvada as monotherapy will be
required to meet the coverage criteria below.
2. Coverage Criteria:
A. HIV Infection
1. Truvada will be approved based on the following criterion:
a. Patient has a confirmed diagnosis of HIV infection
Authorization will be issued for 60 months.
B. Post exposure prophylaxis (PEP) to reduce the risk of HIV infection from
either an occupational or non-occupational known or suspected possible
exposure to the HIV virus
1. Truvada will be approved based on both of the following criteria:

2. Confidential and Proprietary, © 2013 United HealthCare Services, Inc.
2
a. Patient experienced a known or suspected possible exposure to the HIV
virus
-AND-
b. One of the following:
(1) therapy was initiated within 72 hours of exposure
(2) therapy will be initiated within 72 hours of exposure
Authorization will be issued for 1 month
C. Pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1
infection in adults at high risk
1. Initial Therapy
a. Truvada will be approved based on all of the following criteria:
(1) Patient has been determined to be at high risk for HIV-1 infection
-AND-
(2) Patient has received counseling on safe sex practices and HIV infection
risk reduction.
-AND-
(3) Patient has no clinical symptoms consistent with acute viral infection
-AND-
(4) No recent (< 1 month) HIV exposures are suspected
-AND-
(5) Patient has a confirmed negative HIV-1 status within the past week
Authorization will be issued for 6 months.
2. Reauthorization
a. Truvada will be approved based on the following criteria:
(1) Patient has been determined to be at high risk for HIV-1 infection despite

3. Confidential and Proprietary, © 2013 United HealthCare Services, Inc.
3
prior counseling on safe sex practices and HIV infection risk reduction.
-AND-
(2) Patient continues to receive counseling on safe sex practices and HIV
infection risk reduction.
-AND-
(3) Patient has no clinical symptoms consistent with acute viral infection
-AND-
(4) No recent (< 1 month) HIV exposures are suspected
-AND-
(5) Patient has a confirmed negative HIV-1 status within the past 3 months.
Authorization will be issued for 6 months.
3. Additional Clinical Rules: None
4. References:
1. Truvada® [Package Insert]. Foster City, CA: Gilead Sciences, Inc; July 2012.
2. Centers for Disease Control and Prevention. Updated U.S. Public Health Service
guidelines for the management of occupational exposures to HIV and
recommendations for Postexposure Prophylaxis. MMWR 2005;54(No. RR-9):
[inclusive page numbers].
3. Post-exposure prophylaxis to prevent HIV infection: joint WHO/ILO guidelines on
post-exposure prophylaxis (PEP) to prevent HIV infection. Accessed February 26,
2013 from http://www.who.int/hiv/pub/guidelines/PEP/en/